01—Abstract
Summary
Summary of the 10-K filed February 26, 2020. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific's FY2019 10-K shows a strong year: revenue rose 4.9% to $25.54 billiona (about 6% organic growth excluding a $440 million currency headwind and a $153 million acquisition contribution), and operating income climbed 21% to $4.59 billion, lifting operating margin to 18.0% from 15.5%.
Much of that margin expansion was helped by a $478 millionb pre-tax gain on the sale of the Anatomical Pathology business, which was booked within restructuring and other income. Excluding that item, segment income grew about 6% to $5.97 billion, with the reportable segment margin at 23.4% versus 23.1%. Net income rose to $3.70 billion, and diluted EPS reached $9.17 versus $7.24, though the gain and a $184 million loss on early debt extinguishment both affected reported results.
Cash generation and balance-sheet activity were central to the year. Operating cash flow was $4.97 billionc, up from $4.54 billion. The company spent $1.84 billion on acquisitions (led by Brammer Bio at about $1.67 billion), $926 million on capital expenditures, and $1.50 billion on share repurchases, while also paying $297 million in dividends.
Total debt was about $17.75 billiond at carrying value, and the company refinanced roughly $6.4 billion of senior notes. Management guided to an effective tax rate of 8% to 10% for 2020, and a $1.00 billion repurchase authorization remained as of February 26, 2020.
The main forward-looking risks flagged in the filing are the emerging coronavirus outbreak in China, which management said could materially affect operations and sales, plus ongoing U.S.-China tariffs, currency volatility, and Brexit uncertainty. Goodwill and intangibles of roughly $27 billion (about 46% of total assets) carry impairment risk if the business underperforms, and the company is subject to covenant limits of 3.5x maximum leverage and 3.0x minimum interest coverage under its revolver.
02—Key points
Key Highlights
- Revenue grew 4.9% to $25.54 billion (about 6% organic), with Laboratory Products and Services as the largest segment at 41.5% of sales.
- Operating income rose 21% to $4.59 billion, and operating margin expanded to 18.0% from 15.5%, helped by a $478 million gain on the Anatomical Pathology divestiture.
- Diluted EPS increased to $9.17 from $7.24, with net income of $3.70 billion, though results include a $184 million loss on early debt extinguishment.
- Operating cash flow reached $4.97 billion, up from $4.54 billion, supporting $926 million in capex and $1.84 billion in acquisitions.
- Shareholder returns totaled roughly $1.8 billion in 2019 ($1.50 billion in buybacks and $297 million in dividends), with $1.00 billion of repurchase authorization remaining.
- The company carries about $17.75 billion of debt and $27 billion of goodwill and intangibles, creating impairment and leverage sensitivity; revolver covenants cap leverage at 3.5x.
- Management flagged the coronavirus outbreak in China as a potential material risk to operations, supply chains, and sales, with the extent of the impact described as uncertain.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2019filed February 26, 2020Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $25.54B$24.36B | +4.9% |
| R&D Expenses | $1.00B$967.00M | +3.7% |
| SG&A Expenses | $6.14B$6.06B | +1.4% |
| Operating Expenses | $20.95B$20.57B | +1.8% |
| Operating Income | $4.59B$3.78B | +21.4% |
| Interest Expense | $676.00M$667.00M | +1.3% |
| Net Income | $3.70B$2.94B | +25.8% |
| EPS (Basic) | $9.24$7.31 | +26.4% |
| EPS (Diluted) | $9.17$7.24 | +26.7% |
| Shares Outstanding (Basic) | 400.00M402.00M | −0.5% |
| Shares Outstanding (Diluted) | 403.00M406.00M | −0.7% |
05—Questions
Frequently Asked Questions
How much of the 2019 operating income growth came from one-time items?
A substantial portion. The filing records a pre-tax gain of about $478 million on the sale of the Anatomical Pathology business within restructuring and other income, which contributed to the $413 million net restructuring benefit. Segment income, which excludes these items, grew about 6% to $5.97 billion, so the core business improvement was real but more modest than the headline 21% operating income growth.
What is the outlook for the effective tax rate and why does it matter?
Management expects an effective tax rate of 8% to 10% in 2020, reflecting forecast profitability in lower-tax jurisdictions and expected foreign tax credit generation. Cash taxes paid were $896 million in 2019, well above book tax expense of $374 million, mainly because intangible amortization is not deductible for tax purposes. Investors should watch for changes in this rate, since discrete items have historically moved results significantly.
How significant is the coronavirus risk disclosed in the filing?
The company acknowledges that a coronavirus strain surfacing in Wuhan, China in December 2019 could materially affect results through travel restrictions, distribution disruptions, temporary facility closures in China, and reduced customer activity. China represented about $2.75 billion, or roughly 11%, of 2019 revenue. Management stated that the extent of the impact was uncertain at the time of filing.
How is the company's balance sheet positioned after 2019's debt activity?
Total debt at carrying value was about $17.75 billion at year-end 2019, down from $18.99 billion, after the company repaid about $6.36 billion of senior notes and issued $5.64 billion of new notes. Cash was $2.40 billion, and the $2.50 billion revolver was undrawn apart from $72 million of letters of credit. Short-term debt was $676 million, mostly notes due in 2020. The company stated its liquidity is sufficient for at least the next 24 months.
06—Continue